Justin J. Hasford

Partner

Justin Hasford has experience in all areas of intellectual property law. His practice focuses on complex patent litigation at the trial and appellate levels on behalf of pioneer pharmaceutical companies. He has particular experience with cases arising from Abbreviated New Drug Applications (ANDAs) under the Hatch-Waxman Act. Mr. Hasford additionally has litigated healthcare business method patents.

Mr. Hasford also counsels clients on issues of infringement, validity, enforceability, antitrust, unfair competition, licensing, due diligence, and IP portfolio management. He has extensive experience advising clients regarding the interplay between patent and regulatory laws, including Orange Book listing of patents for FDA-approved drugs.

Mr. Hasford regularly speaks on the protection of U.S. intellectual property rights, including at national, regional, and local section meetings of the American Chemical Society, the Pacifichem Congress, and the China International Pharmaceutical and Chemical IP Forum. He also has successfully represented a variety of low-income clients on a pro bono basis.

Highlights

• Ferring B.V. v. Watson Laboratories, Inc. (D. Nev.). Represents Ferring in Hatch-Waxman patent infringement litigations against Watson and Apotex concerning ANDAs seeking FDA approval to market generic versions of Ferring's Lysteda^®.
• Otsuka Pharmaceutical Co. v. Sandoz, Inc. (D.N.J., Fed. Cir.). Represents Otsuka in Hatch-Waxman patent infringement litigations against several ANDA filers seeking FDA approval to market generic versions of Otsuka's Abilify^®. The District of New Jersey entered judgment in favor of Otsuka and against all ANDA filers on all issues.
• Acorda Therapeutics, Inc. v. Apotex Inc. (D.N.J., Fed. Cir.). Represents Acorda in Hatch-Waxman patent infringement litigation concerning Apotex's ANDA seeking FDA approval to market generic versions of Acorda's Zanaflex Capsules^®.
• Eli Lilly and Co. v. Wockhardt Ltd. (S.D. Ind.). Represented Eli Lilly and Company in Hatch-Waxman patent infringement litigations against several ANDA filers seeking FDA approval to market generic versions of Lilly's Cymbalta^®. The Southern District of Indiana entered judgment in favor of Lilly and against all the ANDA filers on all issues.
• Elan Pharmaceuticals, Inc. v. Eon Labs, Inc. (E.D.N.Y., Fed. Cir.). Represented Elan in Hatch-Waxman patent infringement litigations involving Eon's ANDA seeking FDA approval to market generic versions of Skelaxin^®.
• Classen Immunotherapies, Inc. v. King Pharmaceuticals, Inc. (D. Md., Fed. Cir.). Represents Elan Pharmaceuticals in patent infringement litigation brought by Classen. The District of Maryland granted summary judgment of non-infringement in favor of Elan and stayed further action pending the outcome of reexamination proceedings, successfully requested by Elan, before the U.S. Patent and Trademark Office.
• Aventis Pharma, S.A. v. Baxter Healthcare Corp. (D. Del.). Represented Aventis in patent infringement litigation concerning Baxter's Advate^® product for treatment of hemophilia, resolved through confidential arbitration.
• A. Nattermann & Cie GmbH v. Bayer Corp. (E.D. Pa.). Represented Aventis in patent infringement litigation concerning Bayer's Kogenate^® FS product for treatment of hemophilia, settled on confidential terms.
• Pfizer Inc. v. Bayer AG (D. Del.). Represented GlaxoSmithKline in patent infringement litigation concerning Levitra^®, resolved through confidential settlement.
• Engaged in research on free-radical prostaglandin formation in the Department of Pharmacology at Vanderbilt University, 1998-1999; and also conducted research regarding the physical organic chemistry of flavin cofactors, 1996-1998.

Professional Recognition

• Received the Roger D. Middlekauf Award for outstanding service to the Division of Chemistry and the Law of the American Chemical Society, 2011.
• Appointed in December 2008 to serve as deputy general secretary of the Second Beijing International Pharmaceutical and Chemical Intellectual Property Forum in August 2009.

Professional Activities

• American Chemical Society (Division of Chemistry and the Law: chair, 2008; chair-elect, 2007; program chair, 2005-2007 and 2009-2010; secretary, 2011-present)
• American Bar Association
• American Intellectual Property Law Association
• Virginia Bar Association
• District of Columbia Bar

Select Publications

• Coauthor. "Formation of Prostaglandins E2 and D2 via the Isoprostane Pathway: A Mechanism for the Generation of Bioactive Prostaglandins Independent of Cyclooxygenase," Journal of Biological Chemistry, 2003.
• Coauthor. "Reduction of Hg(II)-EDTA by Conformationally Biased Flavins," Tetrahedron Letters, 1998.
• Coauthor. "Linear Free Energy Substituent Effect on Flavin Redox Chemistry," Journal of the American Chemical Society, 1998.
• Coauthor. "Conformational Effects on Flavin Redox Chemistry," Journal of Organic Chemistry, 1997.